Rubicon Research Ltd., backed by US private equity giant General Atlantic, will launch its Rs 1,377.5-crore initial public offering of shares next week. The IPO will be open for subscription between Oct. 9 and Oct. 13, according to the red herring prospectus.
The company will offer shares worth Rs 500 crore in a fresh issue. Promoter General Atlantic Singapore Pte will offload equity worth up to Rs 877.5 crore.
-
NDTV Profit Ignite 2026: Experts See Opportunity In Equities, Stay Bullish For Long-Term -
Buy Right, Sit Tight Does Not Work for Individual Stocks, Says Dinshaw Irani -
'Worst Is Behind': Quant MF Sees Market Bottom, Flags 'Extreme Euphoria' In Midcaps -
India's Mutual Fund Industry Could Become A $1 Trillion Opportunity, Say Fund Managers -
'Foreign Investors Are Baraatis': Raamdeo Agrawal's Take On LTCG Tax -
Stay Invested Through Market Cycles: Raamdeo Agrawal at NDTV Profit Ignite -
Ramesh Damani Remains Bullish On India For Next 20-30 Years, Sees Bargains Amid Market Weakness -
CAS Came After A Long Consultation Process: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFIT IGNITE -
Aim To Cut FPI Onboarding Time From Mth To Five Days: SEBI Chairman Tuhin Kanta Pandey AT NDTV PROFI -
"I Am A Material Man In A Material World': Quantum Advisors' Ajit Dayal On NDTV Profit Ignite
The company will invite investments from large institutions in the pre-IPO anchor round on Oct. 8.
Also Read | Layoffs Are Rising In Tech, But These Skills Are Helping People Unlock Better Pay
Details regarding price band, minimum investment for retail investors, and lot size will be announced via a public advertisement in the coming days.
Proceeds worth Rs 310 crore from the issue will be used for the payment of debt. As on June 30, 2025, the total outstanding borrowing of Rubicon Research is Rs 496 crore.
Funds will also be used for supporting inorganic growth through unidentified acquisitions as well as other strategic initiatives and general corporate purposes.
About Rubicon Research
Maharashtra-based Rubicon Research is a pharmaceutical formulations company with an increasing portfolio of speciality products and drug-device combination products targeting regulated markets.
As on March 31, 2024, Rubicon Research had a portfolio of 69 products approved by the USFDA, 19 new drugs awaiting USFDA's nod and 46 products in various stages of development.
As of June 30, 2025, Rubicon Research has 72 active ANDAs and nine active NDAs approved by, and one over-the-counter (“OTC”) monograph listed with, the USFDA. The company has 17 new products awaiting USFDA ANDA approval and 63 product candidates in various stages of development.
The company applied for the IPO with SEBI in August 2024.
Axis Capital Ltd., IIFL Capital Services Ltd., JM Financial Ltd., and SBI Capital Markets Ltd. are the lead book-running lead managers to the IPO.
Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.
